The first Convention of the Italian Society of Clinical and Experimental Phlebology recently concluded in Rome: Dr. Gargano presented his results and explained the protocol he uses to treat Chronic Cerebrospinal Venous Insufficiency (CCSVI). “CCSVI is a hemodynamic syndrome in which the veins of the chest and neck are unable to effectively remove blood from the central nervous system, due to stenosis and/or malformations. This syndrome is the basis of Prof. Zamboni’s medical theory. It has been associated with multiple sclerosis, but other neurodegenerative diseases could also have CCSVI as a contributing factor.”
“For two years I have been involved in the diagnosis and treatment of CCSVI and to date I have treated about 800 patients. I studied Professor Zamboni’s medical theory during the courses he held in Ferrara and graduated with honors in the Master’s degree in Venous Hemodynamic Surgery from the University of Ferrara, organized by Professor Zamboni himself.
I have mainly treated patients with multiple sclerosis, the most common neurodegenerative disease in young adults aged between 20 and 40, but I have also had excellent results with patients suffering from headaches, chronic fatigue, and fibromyalgia (those positive for CCSVI).
Probably other neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s are also linked to a defect in the veins that drain blood from the brain, but there are no studies on this yet.
The treatment performed is balloon dilatation angioplasty of the jugular and azygos veins. Similar interventions have been performed for years on the arterial system, for example in the treatment of ischemic cardiomyopathy or diabetic foot.
Radiologists in Bulgaria and Poland have also proposed the use of stents, which I do not agree with because currently there are no specific devices for the venous system. I have decided to develop a very precise protocol, which includes neurological and neuropsychological examinations before, one month after, and six months after the procedure to monitor any changes in disease progression.
Patients eligible for surgery are those who test positive on the echo-color Doppler for the detection of chronic cerebrospinal venous insufficiency. The prevalence of CCSVI in MS patients is 97% according to my data, which is also confirmed by phlebographic examination.
Dilatation angioplasty of the jugular and azygos veins is a procedure performed under local anesthesia by puncturing the femoral vein in the groin, through which a catheter is inserted into the venous system up to the neck and chest.
The diagnostic part is called phlebography and is followed by the actual interventional part, which is balloon angioplasty: at the point of stenosis, where the veins narrow, a balloon is positioned, inflated with a pressure gun, and the vein is dilated.
The procedure can sometimes be painful. At the end, all devices are removed and nothing remains in the patients’ veins.
The results are very encouraging. Although it does not cure multiple sclerosis, symptoms associated with this disease very often disappear. We have cases where bladder function returns to normal, paresthesias (sensory disturbances) disappear, walking improves, fatigue almost always decreases or disappears, vision improves in some cases, and in men, sexual disorders (impotence) often disappear.
There are many patient testimonies wanting to share the benefits obtained, and many are published on my website (www.studiomedicogargano.com )
The procedure can be considered safe; in fact, I have never had major complications. The patient goes home the next day with a medical therapy (anticoagulants) and returns after one month and six months for follow-up Doppler scans as well as post-operative neurological and neuropsychological visits. It will be necessary to understand through further studies the correlation between CCSVI and other neurodegenerative diseases and to refine the endovascular treatment of this pathology with the aid of devices such as stents, which are not yet available today.”
Pubblicato in Business
Be the first to comment